Puma Biotechnology (PBYI) News Today $3.37 +0.02 (+0.60%) As of 03:11 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PBYI Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Puma Biotechnology (NASDAQ:PBYI) Stock Price Passes Above Two Hundred Day Moving Average - Should You Sell?Puma Biotechnology (NASDAQ:PBYI) Stock Price Crosses Above 200-Day Moving Average - What's Next?June 24 at 4:35 AM | marketbeat.comInsider Selling: Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Sells 8,100 Shares of StockJune 18, 2025 | insidertrades.comBrian M. Stuglik Sells 8,100 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) StockPuma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) Director Brian M. Stuglik sold 8,100 shares of the stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $3.39, for a total value of $27,459.00. Following the transaction, the director now owns 94,958 shares in the company, valued at $321,907.62. This trade represents a 7.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.June 17, 2025 | marketbeat.comInsider Selling: Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Sells 10,800 Shares of StockPuma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) Director Troy Edward Wilson sold 10,800 shares of Puma Biotechnology stock in a transaction that occurred on Friday, June 13th. The shares were sold at an average price of $3.40, for a total transaction of $36,720.00. Following the sale, the director now owns 43,550 shares of the company's stock, valued at approximately $148,070. The trade was a 19.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.June 17, 2025 | marketbeat.comPuma Biotechnology, Inc. (NASDAQ:PBYI) Director Allison Dorval Sells 11,610 SharesPuma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) Director Allison Dorval sold 11,610 shares of the business's stock in a transaction on Friday, June 13th. The shares were sold at an average price of $3.40, for a total transaction of $39,474.00. Following the transaction, the director now owns 75,390 shares in the company, valued at approximately $256,326. This represents a 13.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.June 17, 2025 | marketbeat.comAlessandra Cesano Sells 12,150 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) StockPuma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) Director Alessandra Cesano sold 12,150 shares of the stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $3.40, for a total value of $41,310.00. Following the completion of the transaction, the director now directly owns 68,850 shares in the company, valued at $234,090. This represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.June 17, 2025 | marketbeat.comJay M. Moyes Sells 22,000 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) StockPuma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) Director Jay M. Moyes sold 22,000 shares of the business's stock in a transaction on Friday, June 13th. The stock was sold at an average price of $3.40, for a total value of $74,800.00. Following the completion of the sale, the director now directly owns 53,322 shares in the company, valued at $181,294.80. This trade represents a 29.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.June 17, 2025 | marketbeat.comAdrian Senderowicz Sells 27,000 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) StockPuma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) Director Adrian Senderowicz sold 27,000 shares of the company's stock in a transaction on Friday, June 13th. The shares were sold at an average price of $3.40, for a total transaction of $91,800.00. Following the completion of the transaction, the director now owns 27,000 shares in the company, valued at approximately $91,800. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.June 17, 2025 | marketbeat.comWith 57% ownership, Puma Biotechnology, Inc. (NASDAQ:PBYI) boasts of strong institutional backingJune 10, 2025 | finance.yahoo.comTwo Sigma Investments LP Purchases 131,916 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)Two Sigma Investments LP lifted its position in Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 266.2% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 181,471 shares of the biopharmaceutical company's stock after purchasing an additional 131,916June 9, 2025 | marketbeat.com78,653 Shares in Puma Biotechnology, Inc. (NASDAQ:PBYI) Purchased by Mackenzie Financial CorpMackenzie Financial Corp bought a new stake in Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 78,653 shares of the biopharmaceutical company's stock, valued at approximately $2June 6, 2025 | marketbeat.comPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)June 4, 2025 | businesswire.comMillennium Management LLC Has $5.78 Million Position in Puma Biotechnology, Inc. (NASDAQ:PBYI)Millennium Management LLC trimmed its holdings in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 34.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,894,126 shares of the biopharmaceutical company's sMay 29, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Buys 165,220 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)D. E. Shaw & Co. Inc. lifted its stake in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 287.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 222,608 shares of the biopharmaceutical company's stock after purchasingMay 26, 2025 | marketbeat.comPuma Biotechnology (NASDAQ:PBYI) Upgraded to Strong-Buy at Wall Street ZenWall Street Zen raised Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research note on Thursday.May 24, 2025 | marketbeat.comDimensional Fund Advisors LP Has $2.64 Million Stock Position in Puma Biotechnology, Inc. (NASDAQ:PBYI)Dimensional Fund Advisors LP grew its holdings in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 24.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 863,760 shares of the biopharmaceutMay 17, 2025 | marketbeat.comPuma Biotechnology's (NASDAQ:PBYI) Earnings Are Of Questionable QualityMay 15, 2025 | uk.finance.yahoo.comPuma Biotechnology (NASDAQ:PBYI) Raised to "Strong-Buy" at StockNews.comStockNews.com upgraded Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research report on Sunday.May 12, 2025 | marketbeat.comPuma Biotech CCO Jeff Ludwig departs, no replacement namedMay 10, 2025 | uk.investing.comPuma Biotechnology targets $192M-$198M NERLYNX revenue for 2025 amid strategic effortsMay 9, 2025 | msn.comPuma Biotechnology Inc (PBYI) Q1 2025 Earnings Call Highlights: Revenue Growth Amidst ChallengesMay 9, 2025 | gurufocus.comPuma Biotechnology Stock Short Interest Report | NASDAQ:PBYI | BenzingaMay 8, 2025 | benzinga.com85,580 Shares in Puma Biotechnology, Inc. (NASDAQ:PBYI) Acquired by Marshall Wace LLPMarshall Wace LLP bought a new stake in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 85,580 shares of the biopharmaceutical company's stock, valued at approximateMay 7, 2025 | marketbeat.comPuma Biotechnology (NASDAQ:PBYI) Cut to "Buy" at StockNews.comStockNews.com cut shares of Puma Biotechnology from a "strong-buy" rating to a "buy" rating in a report on Saturday.May 5, 2025 | marketbeat.comZacks Research Issues Pessimistic Forecast for PBYI EarningsPuma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) - Zacks Research cut their Q2 2025 earnings per share estimates for Puma Biotechnology in a report issued on Wednesday, April 30th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will post earnings of $0.08May 4, 2025 | marketbeat.comAcorn Capital Advisors LLC Purchases Shares of 2,450,711 Puma Biotechnology, Inc. (NASDAQ:PBYI)Acorn Capital Advisors LLC acquired a new stake in Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 2,450,711 shares of the biopharmaceutical company's stock, valuedMay 4, 2025 | marketbeat.comJPMorgan Chase & Co. Increases Stock Position in Puma Biotechnology, Inc. (NASDAQ:PBYI)JPMorgan Chase & Co. increased its stake in Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 182.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 136,897 shares of the biopharmaceutical company's stock after purchaMay 4, 2025 | marketbeat.comQ1 EPS Forecast for Puma Biotechnology Boosted by AnalystPuma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) - Zacks Research increased their Q1 2026 earnings per share (EPS) estimates for Puma Biotechnology in a report released on Wednesday, April 30th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will postMay 3, 2025 | marketbeat.comEr-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer PatientsApril 30, 2025 | globenewswire.comPuma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025April 28, 2025 | businesswire.comPuma Biotechnology (NASDAQ:PBYI) Upgraded to Strong-Buy at StockNews.comStockNews.com upgraded Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a report on Friday.April 27, 2025 | marketbeat.comPuma Biotechnology (PBYI) to Release Quarterly Earnings on ThursdayPuma Biotechnology (NASDAQ:PBYI) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-1-puma-biotechnology-inc-stock/)April 26, 2025 | marketbeat.comPuma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial ResultsApril 24, 2025 | businesswire.comEversept Partners LP Decreases Holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI)Eversept Partners LP cut its stake in Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 23.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 996,102 shares of the biopharmaceutical company's stoApril 24, 2025 | marketbeat.comPuma Biotechnology (NASDAQ:PBYI) Upgraded to "Strong-Buy" at StockNews.comStockNews.com raised shares of Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a report on Wednesday.April 18, 2025 | marketbeat.comKennedy Capital Management LLC Buys 216,329 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)Kennedy Capital Management LLC boosted its position in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 36.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 809,375 shares of the biopharmaceutical companApril 16, 2025 | marketbeat.comPuma Biotechnology: Initiating Hold Rating With Limited Near-Term Upside And Uncertain Pipeline PotentialApril 11, 2025 | seekingalpha.comPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)April 2, 2025 | businesswire.comWINTON GROUP Ltd Sells 270,739 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)WINTON GROUP Ltd decreased its position in Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 87.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 38,241 shares of the biopharmaceutical company's stock after sellApril 2, 2025 | marketbeat.comPuma SE: Undervalued With Tailwinds AheadMarch 31, 2025 | seekingalpha.comPuma Biotechnology, Inc. (NASDAQ:PBYI) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?March 27, 2025 | finance.yahoo.comPUMA SE: This Is The Right Time To BuyMarch 21, 2025 | seekingalpha.comPuma Biotechnology Stock Rises 35% in 6 Months: Here's WhyMarch 20, 2025 | msn.comPuma Biotechnology, Inc. (NASDAQ:PBYI) Shares Purchased by Connor Clark & Lunn Investment Management Ltd.Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 32.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 487,368 sharesMarch 20, 2025 | marketbeat.comPuma Biotechnology (NASDAQ:PBYI) Stock Crosses Above Two Hundred Day Moving Average - Here's What HappenedPuma Biotechnology (NASDAQ:PBYI) Shares Pass Above Two Hundred Day Moving Average - Should You Sell?March 19, 2025 | marketbeat.comPuma Biotechnology (PBYI): One of the Best Short-Term Stocks to Buy Right NowMarch 18, 2025 | msn.comPuma Biotechnology (NASDAQ:PBYI) Stock Rating Lowered by StockNews.comStockNews.com lowered shares of Puma Biotechnology from a "strong-buy" rating to a "buy" rating in a report on Saturday.March 8, 2025 | marketbeat.comZooming In On Puma Biotechnology's EarningsMarch 7, 2025 | finance.yahoo.comPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)March 5, 2025 | businesswire.comPuma Biotechnology to Present at Barclays Annual Global Healthcare ConferenceMarch 5, 2025 | businesswire.com Get Puma Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter. Email Address PBYI Media Mentions By Week PBYI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PBYI News Sentiment▼0.360.62▲Average Medical News Sentiment PBYI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PBYI Articles This Week▼142▲PBYI Articles Average Week Get Puma Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Day One Biopharmaceuticals News Today GH Research News Today UroGen Pharma News Today KalVista Pharmaceuticals News Today Xencor News Today Evolus News Today Stoke Therapeutics News Today Sionna Therapeutics News Today Nuvation Bio News Today ChromaDex News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PBYI) was last updated on 6/24/2025 by MarketBeat.com Staff From Our PartnersIs Tesla a buy right now?Wall Street Legend: Why stocks are very likely to crash in Trump's 2nd Year Legendary investor Marc Chaikin...Chaikin Analytics | SponsoredWhy Is President Trump Fast-Tracking These Companies?Forget about AI… There's a hot new trend on Wall Street… and it's all thanks to President Trump. His administr...InvestorPlace | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredYour portfolio has a dangerous blind spot (fix it now)The next overnight crash could happen any day. Will you be protected or exposed? Register now to learn how som...Ninjacators | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredA grave, grave error.It seems like the world is on fire. Trump’s tariffs are crippling economies worldwide. Canada’s been cri...Porter & Company | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Puma Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Puma Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PBYI Stock Free PBYI Stock Alerts